Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
Type:
Application
Filed:
July 11, 2017
Publication date:
October 26, 2017
Applicant:
COSMO TECHNOLOGIES LIMITED
Inventors:
Roberto VILLA, Massimo PEDRANI, Mauro AJANI, Lorenzo FOSSATI
Abstract: The present invention is directed to an oral pharmaceutical dosage form comprising a capsule containing at least two tablets, each tablet containing at least one different pharmaceutically active ingredient
Type:
Application
Filed:
October 21, 2015
Publication date:
October 26, 2017
Inventors:
NILS WILLIAM AHLGREN, RAGHU CAVATUR, KEVIN CHEN, MATTHEW JAMES KASER, HONGCHUN QIU
Abstract: A pharmaceutical or nutraceutical composition, contains a) a core a), containing a pharmaceutical or a nutraceutical active ingredient and b) a coating layer b), containing a mixture of 80 to 96% by weight of a water-insoluble (meth)acrylate polymer and 4 to 20% by weight of guar gum, wherein the water-insoluble (meth)acrylate polymer contains polymerized units of more than 95 and up to 100% by weight C1-C4-alkyl esters of acrylic acid or of methacrylic acid and less than 5% by weight of acrylic acid or methacrylic acid.
Abstract: Provided are a gene carrier using cell-derived nanovesicles and a method for preparing the same. The gene carrier prepared by inserting a gene into the nanovesicles artificially outbudded from a plasma membrane has excellent delivery efficiency to a target organ and cells, induces long-term regulation of gene expression, and facilitates mass production due to a simple preparation process, and thus can be used as a core technique for the gene or cell therapeutic agent field.
Abstract: This invention relates to amphiphile-polymer particles comprising obtaining a first solution comprising a water-insoluble polymer, a payload and a first amphiphile in a water-miscible solvent; mixing the first solution with an aqueous second solution to form an aqueous composition comprising a particle comprising a water-insoluble polymeric core comprising the water-insoluble polymer; the payload; and the first amphiphile.
Type:
Application
Filed:
October 23, 2015
Publication date:
October 26, 2017
Inventors:
Jinjun Shi, Xi Zhu, Omid C. Farokhzad, Xiaoding Xu, Yanlan Liu, Aude Thiriot, Ulrich Von Andrian
Abstract: The instant invention provides electrospun fiber compositions comprising one or more polymers and one or more biologically active agents. In specific embodiments, the biologically active agents are nerve growth factors. In certain embodiments, the electrospun fiber compositions comprising one or more biologically active agents are on the surface of a film, or a tube. The tubes comprising the electrospun fiber compositions of the invention can be used, for example, as nerve guide conduits.
Type:
Application
Filed:
April 26, 2017
Publication date:
October 26, 2017
Inventors:
Ahmet Hoke, Sing Y. Chew, Ruifa Mi, Kam W. Leong
Abstract: The present technology relates generally to devices for acne treatment, as well as methods for preparing the devices and methods of treatment using the devices. Suitably, the devices comprise a hydrocolloid dressing and an active agent, wherein the amount of the active agent does not reduce the absorption properties of the hydrocolloid dressing. In exemplary embodiments, the active agent is salicylic acid, benzoyl peroxide or sulfur.
Abstract: The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ER?) ligand.
Abstract: The present invention relates to the use of cannabinoids in the treatment of degenerative skeletal muscle disease. In particular the degenerative skeletal muscle disease is Duchenne muscular dystrophy (DMD). Preferably the cannabinoids are one or more of: Cannabidiol (CBD); Cannabidivarin (CBDV); and Tetrahydrocannabivarin (THCV).
Type:
Application
Filed:
October 14, 2015
Publication date:
October 26, 2017
Applicant:
GW Pharma Limited
Inventors:
Vincenzo Di Marzo, Colin Stott, Keith Foster, Fabio Iannotti
Abstract: A method for treating a cancer includes administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising Monobenzone or a pharmaceutical acceptable salt thereof. The cancer is selected from pleural-related cancer, abdominal-related cancer, endocrine-related cancer, gastrointestinal tract-related cancer, osteosarcoma, and skin cancer. The pleural-related cancer is lung cancer. The abdominal-related cancer is selected from bladder cancer, cervical cancer, and kidney cancer. The endocrine-related cancer is selected from prostate cancer, breast cancer, and ovarian cancer. The gastrointestinal tract-related cancer is selected from gastric cancer, hepatic cancer, colorectal cancer, pancreatic cancer, and tongue cancer.
Abstract: The present invention relates to a method of treating or preventing the visual function loss in optic nerve in a subject after crush injury by using 4-(Phenylsulfanyl)butane-2-one (4-PSB-2). The present invention has the ability of enhancing the protection effect of RGCs, preserving the visual function in optic nerve after crush injury, recovering the visual function loss, attenuating apoptosis in optic nerve after injury, and inhibiting the inflammatory responses in optic nerves after ON injury.
Type:
Application
Filed:
October 21, 2016
Publication date:
October 26, 2017
Applicants:
NATIONAL SUN YAT-SEN UNIVERSITY, TZU-CHI UNIVERSITY
Abstract: Methods for modulating Ca2+ signaling in cardiac myocytes by use of xanthohumol are described. Xanthohumol can suppress Ca2+ signaling by suppressing spontaneous activity of the RyR2 receptor. Delivery of xanthohumol to a cardiocyte can be utilized in treatment of cardiac arrhythmia.
Type:
Application
Filed:
April 25, 2017
Publication date:
October 26, 2017
Inventors:
Martin Morad, Lars Cleemann, Juan Jose Arnaiz-Cot
Abstract: The invention features formulations for the local delivery of therapeutically effective doses of curcumin to treat head and neck disorders and upper aerodigestive disorders. Also disclosed are use of the formulations for delivery of other phytochemicals, or the combination of phytochemicals for the treatment of said disorders. Furthermore, these formulations can be used to deliver the recommended daily allowance of vitamins and/or minerals to children or adults.
Type:
Application
Filed:
July 10, 2017
Publication date:
October 26, 2017
Applicant:
Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
Inventors:
Cherie Ann NATHAN, James Douglas BOUDREAUX
Abstract: Compounds, compositions, and formulations, and accompanying methods useful for treating disorders arising from oxidative DNA damage, including oxidative DNA damage resulting from ionizing radiation or other therapy are described herein.
Abstract: The invention relates to compositions comprising a PKC inhibitor and their use in a method of treating or preventing the development of prostate cancer.
Type:
Application
Filed:
April 24, 2017
Publication date:
October 26, 2017
Inventors:
Mildred Acevedo-Duncan, Andre Apostolatos
Abstract: The invention provides a method of treating, inhibiting and/or preventing fatty liver disease in a patient in need thereof, comprising administering an effective amount of a cyclohexenone compound of the following formula (I) to said patient,
Abstract: The invention relates to the manufacturing and use of pharmaceutical compositions of medicines (ophthalmic preparations) comprising a mitochondria-addressed antioxidant and a set of auxiliary substances providing effective treatment for ophtalmological diseases in humans and animals.
Abstract: The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.
Type:
Application
Filed:
April 21, 2017
Publication date:
October 26, 2017
Inventors:
Linda DWOSKIN, Peter Anthony CROOKS, Guangrong ZHENG, Justin R. NICKELL, Zheng CAO, Na-Ra LEE
Abstract: A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of Cinacalcet HCl or a pharmaceutical acceptable salt thereof. The cancer is selected from the group consisting of a pleural-related cancer, an abdominal-related cancer, an endocrine-related cancer, a gastrointestinal tract-related cancer, osteosarcoma, skin cancer, and blood cancer.
Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Abstract: A method for diagnosing a cardiac ischemic event and a kit for detecting biomarkers used in the method. Also provided is a method for treating a PPAR-related disorder by administering a pharmaceutical composition containing one or more long chain fatty acids.
Type:
Application
Filed:
October 7, 2015
Publication date:
October 26, 2017
Inventors:
Patrick Alton Gladding, Mia Jullig, Silas Villas-Boas, Seif El-Jack
Abstract: Disclosed are methods and topical formulations for treating and/or preventing cell proliferative diseases and disorders including breast cancer and ductal carcinoma is situ (DCIS) using local transdermal therapy (LTT). The disclosed methods typically include administering topically to the breast or breasts of the patient a topical formulation comprising an effective dose of the tamoxifen metabolite, N-desmethyl-4-hydroxytamoxifen (i.e., endoxifen or ENX) for treating breast cancer. The topical formulation may be described as a transdermal formulation and the topical formulation may comprise, consist essentially of, or consist of endoxifen as an active ingredient.
Abstract: The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Abstract: The present invention relates to extended release liquid compositions of metformin. The extended release liquid compositions are in the form of suspensions or reconstituted powder for suspensions. Said extended release liquid compositions comprise cores of metformin coated with a release-controlling agent, wherein the coated cores are dispersed in a suspension base. Said extended release liquid compositions provide the desired uniform extended release profile throughout the shelf-life of the composition. Furthermore, said extended release liquid compositions are bioequivalent to a reference composition. It also relates to processes for the preparation of said extended release liquid compositions.
Type:
Application
Filed:
May 2, 2016
Publication date:
October 26, 2017
Inventors:
Romi Barat SINGH, Ashish KUMAR, Rajesh Srikrishan SHEAR, Satish Kumar JAIN, Paras P. JAIN
Abstract: The present invention relates to linear guanidine derivatives, methods of preparation, uses and pharmaceutical compositions thereof. The compounds of Formulas 1 or 2 exhibit high antimicrobial activity against Gram positive and Gram negative bacteria.
Type:
Application
Filed:
October 9, 2015
Publication date:
October 26, 2017
Applicant:
LEAD DISCOVERY SIENA S.R.L.
Inventors:
Maurizio BOTTA, Giorgio MACCARI, Stefania SANFILIPPO, Filomena DE LUCA, Jean-Denis DOCQUIER, Davide DEODATO
Abstract: An object to be achieved by the present invention is to provide a novel antiallergic agent using, as an active ingredient, a compound that has heretofore not been known to have an antiallergic action. The present invention provides an antiallergic agent, including a compound represented by the formula (I) or a salt thereof: where R1 and R2, which are identical to or different from each other, each represent an alkyl group having 1 to 3 carbon atoms, m represents an integer of from 0 to 3, and n represents an integer of from 1 to 3.
Abstract: The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.
Type:
Application
Filed:
June 26, 2017
Publication date:
October 26, 2017
Applicant:
National Institute of Biological Sciences, Beijing
Inventors:
Zhiyuan Zhang, Xiaodong Wang, Yaning Su, Hanying Ruan, Yan Ren
Abstract: Pharmaceutical compositions for reducing frequency of urination are disclosed. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier. Also disclosed are methods of making and using the pharmaceutical compositions.
Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
Type:
Application
Filed:
September 3, 2015
Publication date:
October 26, 2017
Applicant:
ViiV Healthcare UK (No.5) Limited
Inventors:
Makonen BELEMA, John A. BENDER, Brett BENO, Robert G. GENTLES, Guo LI, Nicholas A. MEANWELL, Annapurna PENDRI, Zhong YANG, Shirong ZHU
Abstract: The present disclosure relates to methods of using a compound to induce regeneration of hematopoietic stem cells or increase the recovery of red blood cells. In some aspects, the present methods can be used to with or in place of erythropoietin in patients to mitigate the side effects of erythropoietin.
Type:
Application
Filed:
May 12, 2015
Publication date:
October 26, 2017
Inventors:
Chengcheng ZHANG, Yi LIU, Junke ZHENG, Mi DENG, Chuo CHEN, Jiawei LIU
Abstract: The present invention relates to a novel method for the treatment and/or prophylaxis of a tau-mediated neurodegenerative disease and/or of a tau-mediated neurodegenerative pathological condition, especially of a neurodegenerative disease and/or of a neurodegenerative pathological condition associated with and/or accompanied by tau aggregation, and in particular for the treatment and/or prophylaxis of a tauopathy; compounds and/or agents and compositions for such treatment and/or prophylaxis, and the manufacture of the compounds and/or agents and compositions suitable for the said treatment and/or prophylaxis. In this regard, the present invention relates especially to the use of compounds acting as PERK activator, a prodrug thereof, a derivative thereof and/or a pharmaceutically acceptable salt of any thereof, as a medicament.
Type:
Application
Filed:
August 14, 2015
Publication date:
October 26, 2017
Inventors:
Günter HÖGLINGER, Julius BRUCH, Thomas RÖSLER
Abstract: Methods for preparing sterilized baclofen solutions include adjusting the pH to below a desired pH, and steam sterilizing the solution with adjusted pH, which results in the solution having the desired pH. Such solutions may also have low concentrations of 4-CPP. Injectable baclofen solutions having greater than 2 mg/mL baclofen include between 5 mM and 25 mM of a phosphate or sulfate species. The solution has an ionic strength equivalent of about 1.5 M NaCl. The present application also provides baclofen formulations for use in treating spasticity, brain injury, cerebral palsy, spinal cord injury, cervical injury, multiple sclerosis, thoracic injury, or withdrawal symptoms.
Type:
Application
Filed:
February 7, 2017
Publication date:
October 26, 2017
Applicant:
SAOL INTERNATIONAL LIMITED
Inventors:
Michael C. SCHMITZ, Corinne DOMINGUEZ, Thomas E. KEENE, Deanna S. LANE, Lanchi T. LE, Jianwei LI, Ngoc T. LU, Carmen E. SNAZA
Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
Abstract: The present invention relates to a neurodegenerative disease treatment use, which is a novel use of Ramalin, and, more specifically, to a composition for preventing or treating neurodegenerative diseases, containing Ramalin, which has an inflammasome and BACE1 expression inhibitory activity. Ramalin according to the present invention has an effect of improving a cognitive ability by inhibiting the expression of an inflammatory factor, which contains an NLRP inflammasome protein, and BACE1, and is thus useful for preventing or treating memory disorder and neurodegenerative diseases.
Type:
Application
Filed:
October 24, 2014
Publication date:
October 26, 2017
Inventors:
Joung Han Yim, Il-Chan Kim, Se Jong Han, Dong-Gyu Jo
Abstract: Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.
Type:
Application
Filed:
July 7, 2017
Publication date:
October 26, 2017
Inventors:
Umut Ozcan, Joseph Majzoub, Ralph Mazitschek, Isin Cakir, Serkan Cabi
Abstract: The invention relates to a solid pharmaceutical preparation comprising levothyroxine sodium, gelatine, citric acid and a filler. The solid pharmaceutical preparation has an improved stability.
Type:
Application
Filed:
July 10, 2017
Publication date:
October 26, 2017
Applicant:
MERCK PATENT GMBH
Inventors:
Hiltrud LINDENBLATT, Thomas T. FRANK, Reiner VONDERSCHMITT
Abstract: Provided herein are compositions comprising eicosapentaenoic acid (EPA) and polar lipids (e.g., glycolipids and phospholipids), and which do not contain any docosahexaenoic acid (DHA) or esterified fatty acids.
Type:
Application
Filed:
April 21, 2017
Publication date:
October 26, 2017
Applicant:
Qualitas Health, Ltd.
Inventors:
Brian J. WAIBEL, Hans SCHONEMANN, Val KRUKONIS, Michael KAGAN
Abstract: Disclosed herein is a formulation that can take the form of an emulsion which contains total enteral or parenteral nutrition for a recipient subject. The formulation includes as the sole fat components: (i) medium chain triglycerides; and (ii) very long chain fatty acids selected from (a) very long chain omega-3 polyunsaturated fatty acids; and (b) docosahexaenoic acid and arachidonic acid in a ratio of about 10:1 (v/v or w/w) to about 2000:1 (v/v or w/w). The sole fat components provide about 10% to about 90% total calories of the formulation, and the medium chain triglycerides provide about 25%-95% total fat calories of the formulation. Methods and kits for utilizing the formulation and for treating various disorders and diseases that involve an inflammatory response are also disclosed.
Type:
Application
Filed:
September 10, 2015
Publication date:
October 26, 2017
Applicants:
CHILDREN'S MEDICAL CENTER CORPORATION, BETH ISRAEL DEACONESS MEDICAL CENTER
Abstract: The present invention provides uses of chlorogenic acid in the preparation of medicaments for treatment of mesoglioma. Chlorogenic acid according to the present invention has an inhibitory action against mesoglioma, and can inhibit the growth of brain tumor stem cells, thus can partly substitute chemoradiation. Chlorogenic acid can alleviate the unwell response of patients caused by chemoradiation, and become a new medicinal therapeutic means and choose for treatment of mesoglioma.
Abstract: A method of treating a leukemia comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a compound of Formula (I) and/or (II) having the structure: OR2 R R1O n OR2 R R1O n I II wherein: 10 ---- represents a single or a double bond; R is OH when C----R is C—R, and R is O when C----R is C?R; n is 1, 3, 5 or 7; and R1 and R2 are independently hydrogen or acetyl, and/or isomers, stereoisomers or solvates thereof and/or mixtures thereof.
Type:
Application
Filed:
October 9, 2015
Publication date:
October 26, 2017
Inventors:
Paul Anthony SPAGNUOLO, Aaron David SCHIMMER
Abstract: A method of treating insulin resistance includes administering to a subject a pharmaceutical composition comprising diethyl azelate. For example, a method of treating insulin resistance includes orally administering to a subject a pharmaceutical composition that includes diethyl azelate at a dosage range from about 0.1 mg/kg/day to about 10 mg/kg/day.
Abstract: The subject invention provides a method for treating a subject afflicted with a form of multiple sclerosis (MS) or presenting a clinically isolated syndrome (CIS) comprising periodically administering to the subject an amount of laquinimod and an amount of a compound of formula (I): as described herein. The subject invention also provides packages and pharmaceutical compositions comprising laquinimod and a compound of formula (I) as described herein. The subject invention further provides uses of said compounds, pharmaceutical compositions and packages in treating a subject afflicted with a form of MS or presenting a CIS.
Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.
Type:
Application
Filed:
July 10, 2017
Publication date:
October 26, 2017
Inventors:
Gee-Hong Kuo, Rui Zhang, Aihua Wang, Alan R. DeAngelis
Abstract: Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).
Type:
Application
Filed:
October 7, 2015
Publication date:
October 26, 2017
Inventors:
Thomas Baiga, Michael Downes, Ronald Evans, Arthur Kluge, Bharat Lagu, Masanori Miura, Sunil Kumar Panigrahi, Michael Patane, Susanta Samajdar, Ramesh Senaiar, Taisuke Takahashi
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Type:
Application
Filed:
July 7, 2017
Publication date:
October 26, 2017
Inventors:
Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Abstract: Topical alcohol-free thermo labile oily foam composition comprising (i) at least one active pharmaceutical ingredient or ectoparasitic active ingredient; (ii) at least about 20% w/w of at least one lipophilic component; (iii) at least about 10% w/w of at least one non-ionic surfactant; (iv) at least about 0.5% w/w of at least one fatty alcohol or fatty acid or ester thereof with melting point above 30° C., and; (v) at least about 7% w/w of propellant selected from propane, butane, isobutane and combinations thereof; said composition optionally comprising at least about 5% to about 70% w/w of a hydrophilic component, optionally comprising up to about 5% w/w hydrogenated oil and optionally comprising a penetration enhancer.
Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
Type:
Application
Filed:
July 6, 2017
Publication date:
October 26, 2017
Applicant:
Humanetics Corporation
Inventors:
Edmund Joseph Elder, JR., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk